Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Journal for Nurses in Staff Development : JNSD : Official Journal of the National Nursing Staff Development Organization|December 2, 2010
Staff's perceptions of voluntary assertiveness skills trainingSarah McVanel, Beth MorrisPsychiatric Rehabilitation Journal|November 2, 2006
Implementing program-wide awareness about recovery in a large mental health and addictions programSarah McVanel-Viney, Jodi Younger, Winnie Doyle, et al.Journal of Sports Sciences|September 22, 2007
Variable-cam resistance training machines: do they match the angle - torque relationship in humans?Jonathan Folland, Beth MorrisChronic Illness|October 27, 2020
The information and support needs of patients living with inflammatory bowel disease: A qualitative studyPaige Karadag, Beth Morris, Kerry WoolfallClinical Pharmacology in Drug Development|October 31, 2023
The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose StudyRajinder Bhardwaj, Beth Morris, Richard Bertz, et al.Headache|August 27, 2025
The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open-label, single-dose, parallel-group studyRajinder Bhardwaj, Beth Morris, Richard Bertz, et al.Clinical Pharmacology in Drug Development|January 4, 2024
A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy ParticipantsRajinder Bhardwaj, Beth Morris, Kyle Matschke, et al.Headache|October 4, 2024
Characterization of rimegepant drug-drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolamRajinder Bhardwaj, Beth Morris, Kyle T Matschke, et al.Headache|May 4, 2023
Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participantsRajinder Bhardwaj, Joseph C Stringfellow, Beth Morris, et al.Clinical Pharmacology in Drug Development|April 19, 2023
Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group StudyRajinder Bhardwaj, Andrea Ivans, Joseph Stringfellow, et al.Pageof 3